Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug designed using generative AI, to treat idiopathic pulmonary ...

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

A biotech that uses artificial intelligence to assist its drug discovery efforts has relocated its headquarters from New York ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

The UAE BioTech Symposium will be hosted in partnership with AmCham Abu Dhabi's BioTech Committee and Masdar City <li /> T ...

Sunrise Senior Living is pleased to announce the grand opening of Sunrise of Killarney, a new long-term care community designed to provide exceptional care and vibrant living experiences for its ...

Insilico Medicine Inc. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

To find out more, pharmaphorum spoke with Alex Zhavoronkov, founder and CEO of Insilico Medicine, who will be giving the keynote address, ‘Multi-modal generative AI and robotics for drug ...